Healthcare provider profile · identity verified

Laura C Vargas, MD

Family Practice · FONTANA, CA · NPI 1982915468

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	360	142
Amlodipine Besylate	Amlodipine Besylate	217	87
Omeprazole	Omeprazole	149	49
Lisinopril	Lisinopril	142	49
Losartan Potassium	Losartan Potassium	135	51
Levothyroxine Sodium	Levothyroxine Sodium	129	49
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	127	36
Rosuvastatin Calcium	Rosuvastatin Calcium	124	48
Alendronate Sodium	Alendronate Sodium	112	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	112	45
Metformin Hcl	Metformin Hcl	108	44
Trazodone Hcl	Trazodone Hcl	89	27
Pantoprazole Sodium	Pantoprazole Sodium	78	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	74	28
Atenolol	Atenolol	70	26
Hydrocortisone	Hydrocortisone	70	37
Tramadol Hcl	Tramadol Hcl	68	16
Meloxicam	Meloxicam	63	32
Furosemide	Furosemide	62	25
Bisoprolol Fumarate	Bisoprolol Fumarate	59	24
Potassium Chloride	Potassium Chloride	57	21
Glipizide	Glipizide	56	24
Terazosin Hcl	Terazosin Hcl	52	20
Albuterol Sulfate Hfa	Albuterol Sulfate	50	28
Cephalexin	Cephalexin	49	40
Sertraline Hcl	Sertraline Hcl	48	21
Pradaxa	Dabigatran Etexilate Mesylate	47	12
Gabapentin	Gabapentin	46	22
Jardiance	Empagliflozin	46	16
Breyna	Budesonide/Formoterol Fumarate	44	16
Doxycycline Monohydrate	Doxycycline Monohydrate	43	34
Metoprolol Tartrate	Metoprolol Tartrate	42	17
Simvastatin	Simvastatin	42	15
Eliquis	Apixaban	41	suppressed
Humulin N	Insulin Nph Human Isophane	40	11
Temazepam	Temazepam	35	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	33	16
Tamsulosin Hcl	Tamsulosin Hcl	33	11
Hydralazine Hcl	Hydralazine Hcl	31	12
Prednisone	Prednisone	31	22
Fluocinolone Acetonide	Fluocinolone Acetonide	28	14
Metformin Hcl Er	Metformin Hcl	28	14
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	26	26
Azelastine Hcl	Azelastine Hcl	26	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	26	suppressed
Lactulose	Lactulose	25	suppressed
Methocarbamol	Methocarbamol	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	24	suppressed
Acyclovir	Acyclovir	23	suppressed
Ibuprofen	Ibuprofen	23	14
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Lidocaine	Lidocaine	22	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Tadalafil	Tadalafil	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	18
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	17	17
Carvedilol	Carvedilol	17	suppressed
Finasteride	Finasteride	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Glipizide Er	Glipizide	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Ozempic	Semaglutide	15	suppressed
Amoxicillin	Amoxicillin	14	14
Montelukast Sodium	Montelukast Sodium	14	suppressed
Digoxin	Digoxin	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Fluocinonide	Fluocinonide	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	13	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Naproxen	Naproxen	11	suppressed
Risperidone	Risperidone	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error